Gynecomastia and hypertension in a patient treated with posaconazole

George R Thompson 3rd; Prasanth N Surampudi; Alex Odermatt

doi:10.1002/ccr3.3376

Gynecomastia and hypertension in a patient treated with posaconazole

Clin Case Rep. 2020 Sep 28;8(12):3158-3161. doi: 10.1002/ccr3.3376. eCollection 2020 Dec.

Authors

George R Thompson 3rd¹, Prasanth N Surampudi², Alex Odermatt³

Affiliations

¹ Department of Internal Medicine Division of Infectious Diseases University of California Davis Medical Center Davis CA USA.
² Department of Internal Medicine Division of Endocrinology University of California Davis Medical Center Davis CA USA.
³ Swiss Centre for Applied Human Toxicology and Division of Molecular and Systems Toxicology Department of Pharmaceutical Sciences University of Basel Basel Switzerland.

Abstract

Posaconazole therapy may lead to increased serum estradiol levels and development of gynecomastia. Early detection by endocrine hormone measurements may help preventing gynecomastia.

Keywords: 11beta‐hydroxylase; adverse drug effect; estradiol; gynecomastia; hypertension; hypokalemia; posaconazole.

Publication types

Case Reports